Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of human breast cancer cell line SUM190 treated with Nectin4 ADC

ABSTRACT: RNA-seq of human breast cancer cell line SUM190 treated with Nectin4 ADC

PROVIDER: PRJEB52614 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR9681191_1.fastq.gz	Fastqsanger.gz
	ERR9681191_2.fastq.gz	Fastqsanger.gz
	ERR9681192_1.fastq.gz	Fastqsanger.gz
	ERR9681192_2.fastq.gz	Fastqsanger.gz
	ERR9681193_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

RNA-seq of human breast cancer cell line SUM190 treated with Nectin4 ADC

Project description:Nectin-4 is a new therapeutic target in various carcinomas. We were interested in resistance to anti-nectin 4 ADC in breast cancer and the way to overcome it. Tumor RNAs were extracted from sensitive and resistant pre-clinical models. RNA-Seq libraries were created using Truseq RNA-Seq Library kit.

2022-05-14 | E-MTAB-11682 | biostudies-arrayexpress

Comparative genomic hybridization (CGH) of human breast cancer cell line SUM190 treated with Nectin4 ADC

Project description:Nectin-4 is a new therapeutic target in various carcinomas. We were interested in resistance to anti-nectin 4 ADC in breast cancer and the way to overcome it. Tumor DNA were extracted from sensitive and resistant pre-clinical models. Genomic profiles of samples were established by using array-CGH onto 4×180K CGH microarrays.

2022-05-01 | E-MTAB-11681 | biostudies-arrayexpress

Next Generation Sequencing of TGS24-treated human breast cancer cell line

Project description:Next Generation Sequencing of TGS24-treated human breast cancer cell line

| PRJNA707353 | ENA

Next Generation Sequencing of TGS24-treated human breast cancer cell line

Project description:We report the differential gene expression of TGS24-treated breast cancer cells

2022-03-06 | GSE168403 | GEO

Metagenome of ADC

Project description:Metagenome of ADC

| PRJNA670640 | ENA

Microarray data from patients samples with triple negative breast cancer

Project description:The genomic studies was designed to identify genes differentially expressed in tumor versus normal breast tissue. We aimed at identifying novel Antibody Drug Conjugate (ADC) targets that could be used to treat Triple Negative Breast Cancer (TNBC). Comparative genomic studies between normal breast and TNBC tissues, together with proteomic and bioinformatic analyses resulted in the elaboration of a catalog of potential ADC targets.

2021-10-12 | GSE185645 | GEO

RNA-seq tumor immunome analysis of murine breast cancer model EMT6-hHER2 responsive to novel antibody drug conjugate T-PNU

Project description:An orthotopic murine breast cancer model was created by transfecting the human HER2 gene into the breast cancer cell line EMT6 resulting in EMT6-hHER2. Previous in vivo tumor treatments with trastuzumab, trastuzumab-emtansine (T-DM1) and a novel antibody drug conjugate (ADC) T-PNU (provided by NBE therapeutics and carrying the highly potent anthracycline analogue PNU-159682) revealed that EMT6-hHER2 tumors are unresponsive to standard therapy treatments of trastuzumab and T-DM1, but respond well to the novel ADC T-PNU. Identifying immunogenic cell death properties of T-PNU, we postulated a therapeutic relevance for T-PNU mediated immune modulation of the tumor microenvironment. In order to identify the transcriptional pathways underlying the T-PNU anti-tumor response, we performed RNA-sequencing analysis of CD45+ tumor-derived cells from differently treated cohorts (untreated, trastuzumab, T-DM1, T-PNU; n=6).

2018-10-06 | GSE120888 | GEO

HAX1-interactome in breast cancer cell line (MCF7)

Project description:The MCF7 cell line represents a typical epithelial cell line and corresponds to luminal A breast cancer (estrogen-responsive). Overexpression of HAX1 was demonstrated in MCF7 cell line as well as in breast cancer samples, suggesting a role of HAX1 in breast cancer progression. HAX1 is a 32-kDa protein of unknown structure, involved in the regulation of apoptosis, cell migration and calcium homeostasis. It was also shown to bind mRNA. Scarcity of structural elements and the presence of a disordered region, inferred from HAX1 sequence, suggests that HAX1 is intrinsically disordered, and may have many protein-protein interactions. So far about 40 different proteins were characterized as HAX1 protein partners. In the present work, applying immunoaffinity chromatography coupled with mass spectrometry, we identified new candidates for HAX1 binding partners in breast cancer cells. Newly identified proteins may be divided into three, partially overlapping groups: cytoskeleton-associated proteins, GTP-ase associated proteins and RNA-binding proteins. These results imply that HAX1 has more protein partners than hitherto described. Subsequent analysis of these interactions may shed some light into molecular mechanisms of HAX1 functions.

2019-11-14 | PXD007888 | Pride

Breast cancer cells treated with milk extracellular vesicles

Project description:4T1 breast cancer cell treated with bovine milk extracellular vesicles

2021-03-18 | PXD024762 | Pride

INPP4B over-expressed INPP4B MCF-7 luminal breast cancer cell line

Project description:INPP4B over-expressed INPP4B MCF-7 luminal breast cancer cell line

2020-06-01 | MSV000085526 | MassIVE